Vireo Growth (VREOF) Receivables - Net (2020 - 2026)
Vireo Growth (VREOF) reported Receivables - Net of $2.0 million for Q1 2026, down 17.51% on a YoY basis from $2.4 million in Q1 2025, and down 84.25% sequentially from $12.7 million in Q4 2025.
Vireo Growth (VREOF) Receivables - Net (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Receivables - Net data on file, last reported at $2.0 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Net fell 17.51% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 17.51% YoY), and the FY2025 full-year result was $12.7 million, up 342.48% from the prior year.
- Receivables - Net slipped to $2.0 million in Q1 2026, from $12.7 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $12.7 million in Q4 2025 to a low of $109649.0 in Q4 2022.
- A 5-year average of $3.4 million and a median of $2.3 million in 2024 frame the typical range for Receivables - Net.
- Across the five-year window, Receivables - Net sank 97.56% in 2022 and soared 497.56% in 2023, its largest moves.
- Tracing VREOF's Receivables - Net over 5 years: stood at $109649.0 in 2022, then soared by 497.56% to $655217.0 in 2023, then jumped by 338.05% to $2.9 million in 2024, then soared by 342.48% to $12.7 million in 2025, then slumped by 84.25% to $2.0 million in 2026.
- Business Quant data shows VREOF's Receivables - Net at $2.0 million in Q1 2026, $12.7 million in Q4 2025, and $988641.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 12.70 Mn |
| Dec 31, 2025 | 12.70 Mn |
| Sep 30, 2025 | 988,641.00 |
| Sep 30, 2025 | 988,641.00 |
| Jun 30, 2025 | 9.14 Mn |
| Jun 30, 2025 | 9.14 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Dec 31, 2024 | 2.87 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Sep 30, 2024 | 2.67 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 655,217.00 |
| Dec 31, 2023 | 655,217.00 |